Rubric Capital Management (New York)’s CytomX Therapeutics CTMX Stock Holding History

Rubric Capital Management (New York)’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-2,406,449	Closed	-$3.85M	–	76
2022 Q4	$3.85M	Hold	2,406,449	–	–	0.17%	77
2022 Q3	$3.49M	Hold	2,406,449	–	–	0.18%	72
2022 Q2	$4.4M	Hold	2,406,449	–	–	0.23%	65
2022 Q1	$6.42M	Hold	2,406,449	–	–	0.23%	56
2021 Q4	$10.4M	Buy	+2,406,449	New	+$14.1M	0.49%	46

Other funds holding CTMX

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BCM

Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Rubric Capital Management (New York)'s CTMX Position: Q1 2023 in Review

Rubric Capital Management (New York) sold out of CytomX Therapeutics (CTMX) in Q1 2023, closing a stake of 2,406,449 shares — an estimated $3.85M sold.

Rubric Capital Management (New York) first reported a position in CTMX in Q4 2021 and held it in 5 quarters. The position peaked at $10.4M in Q4 2021. 75 funds tracked by Wall St. Rank hold CTMX as of Q1 2023.

Rubric Capital Management (New York) reported no remaining CytomX Therapeutics position as of Q1 2023 after selling out during the quarter.
Rubric Capital Management (New York) sold 2,406,449 CytomX Therapeutics shares in Q1 2023, an estimated $3.85M.
Rubric Capital Management (New York) first reported a position in CytomX Therapeutics in Q4 2021 and held it in 5 quarters.
Rubric Capital Management (New York)'s CytomX Therapeutics position peaked at $10.4M in Q4 2021.
75 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2023.

Based on Rubric Capital Management (New York)'s 13F filing for Q1 2023, filed 12 May 2023.